LSD1 inhibitor therapy is an emerging promising new cancer therapy not only in AML [166] but other solid forms of cancer including Non-Small Cell Lung Cancer (NSCLC) and childhood sarcomas [164,167]. The gene discussed is KDM1A; the disease is acute myeloid leukemia.